Cargando…

Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2

The number of patients with SARS-CoV-2 infection continues to increase, and it has become a global pandemic. Although there is an urgent need to establish an effective treatment, the medication available for dialysis patients has been limited. An antibody cocktail containing two SARS-CoV-2-neutrariz...

Descripción completa

Detalles Bibliográficos
Autores principales: Arikawa, Shigehisa, Fukuoka, Kazuhito, Nakamoto, Keitaro, Kunitomo, Rie, Matsuno, Yuki, Shimazaki, Teppei, Saraya, Takeshi, Kawakami, Takahisa, Kishimoto, Mitsumasa, Komagata, Yoshinori, Kurai, Daisuke, Ishi, Haruyuki, Kaname, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856930/
https://www.ncbi.nlm.nih.gov/pubmed/35182277
http://dx.doi.org/10.1007/s10157-021-02151-3
_version_ 1784653947377549312
author Arikawa, Shigehisa
Fukuoka, Kazuhito
Nakamoto, Keitaro
Kunitomo, Rie
Matsuno, Yuki
Shimazaki, Teppei
Saraya, Takeshi
Kawakami, Takahisa
Kishimoto, Mitsumasa
Komagata, Yoshinori
Kurai, Daisuke
Ishi, Haruyuki
Kaname, Shinya
author_facet Arikawa, Shigehisa
Fukuoka, Kazuhito
Nakamoto, Keitaro
Kunitomo, Rie
Matsuno, Yuki
Shimazaki, Teppei
Saraya, Takeshi
Kawakami, Takahisa
Kishimoto, Mitsumasa
Komagata, Yoshinori
Kurai, Daisuke
Ishi, Haruyuki
Kaname, Shinya
author_sort Arikawa, Shigehisa
collection PubMed
description The number of patients with SARS-CoV-2 infection continues to increase, and it has become a global pandemic. Although there is an urgent need to establish an effective treatment, the medication available for dialysis patients has been limited. An antibody cocktail containing two SARS-CoV-2-neutrarizing antibodies, REGN-COV2 has been granted special approval for COVID-19 in Japan, since July 2021, and this intravenous preparation can be used for dialysis patients. At our hospital, we had 22 hemodialysis patients with COVID-19, and five of them were treated with REGN-COV2. On admission, four of the five patients had moderate disease (pneumonia but O(2) inhalation) and one patient had mild disease (not having pneumonia). The mean duration of hospitalization treated with REGN-COV2 was 10.2 ± 2.86 days (mean ± SD), which was less than half, compared to patients untreated of similar severity on admission (22.12 ± 15.5). The time to fever resolution was average 7 days, and no cases progressed to severe illness or death. Among these patients, no obvious adverse reactions were shown. Although more studies with a larger number of patients could be needed for a rigorous evaluation of the effect, our result suggests that REGN-COV2 may be safe and having the possibilities in preventing severe disease in hemodialysis patients. Given the difficulty in securing inpatient beds tend to be in short supply, the strategy combined with neutralizing antibody could be beneficial for end-stage kidney disease (ESKD) patients with hemodialysis who are at high risk of severe disease.
format Online
Article
Text
id pubmed-8856930
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-88569302022-02-22 Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2 Arikawa, Shigehisa Fukuoka, Kazuhito Nakamoto, Keitaro Kunitomo, Rie Matsuno, Yuki Shimazaki, Teppei Saraya, Takeshi Kawakami, Takahisa Kishimoto, Mitsumasa Komagata, Yoshinori Kurai, Daisuke Ishi, Haruyuki Kaname, Shinya Clin Exp Nephrol Original Article The number of patients with SARS-CoV-2 infection continues to increase, and it has become a global pandemic. Although there is an urgent need to establish an effective treatment, the medication available for dialysis patients has been limited. An antibody cocktail containing two SARS-CoV-2-neutrarizing antibodies, REGN-COV2 has been granted special approval for COVID-19 in Japan, since July 2021, and this intravenous preparation can be used for dialysis patients. At our hospital, we had 22 hemodialysis patients with COVID-19, and five of them were treated with REGN-COV2. On admission, four of the five patients had moderate disease (pneumonia but O(2) inhalation) and one patient had mild disease (not having pneumonia). The mean duration of hospitalization treated with REGN-COV2 was 10.2 ± 2.86 days (mean ± SD), which was less than half, compared to patients untreated of similar severity on admission (22.12 ± 15.5). The time to fever resolution was average 7 days, and no cases progressed to severe illness or death. Among these patients, no obvious adverse reactions were shown. Although more studies with a larger number of patients could be needed for a rigorous evaluation of the effect, our result suggests that REGN-COV2 may be safe and having the possibilities in preventing severe disease in hemodialysis patients. Given the difficulty in securing inpatient beds tend to be in short supply, the strategy combined with neutralizing antibody could be beneficial for end-stage kidney disease (ESKD) patients with hemodialysis who are at high risk of severe disease. Springer Nature Singapore 2022-02-18 2022 /pmc/articles/PMC8856930/ /pubmed/35182277 http://dx.doi.org/10.1007/s10157-021-02151-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Arikawa, Shigehisa
Fukuoka, Kazuhito
Nakamoto, Keitaro
Kunitomo, Rie
Matsuno, Yuki
Shimazaki, Teppei
Saraya, Takeshi
Kawakami, Takahisa
Kishimoto, Mitsumasa
Komagata, Yoshinori
Kurai, Daisuke
Ishi, Haruyuki
Kaname, Shinya
Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
title Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
title_full Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
title_fullStr Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
title_full_unstemmed Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
title_short Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2
title_sort effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without regn-cov2
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856930/
https://www.ncbi.nlm.nih.gov/pubmed/35182277
http://dx.doi.org/10.1007/s10157-021-02151-3
work_keys_str_mv AT arikawashigehisa effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT fukuokakazuhito effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT nakamotokeitaro effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT kunitomorie effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT matsunoyuki effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT shimazakiteppei effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT sarayatakeshi effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT kawakamitakahisa effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT kishimotomitsumasa effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT komagatayoshinori effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT kuraidaisuke effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT ishiharuyuki effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2
AT kanameshinya effectivenessofneutralizingantibodycocktailinhemodialysispatientsacaseseriesof20patientstreatedwithorwithoutregncov2